Committee Chairman Chuck Grassley, R-Iowa, and ranking member Sen. Ron Wyden D-Oregon, have asked Cigna, CVS, Humana, OptumRx and Prime Therapeutics to testify on Capitol Hill.
The senators have been critical of PBMs, which negotiate drug benefits with drugmakers on behalf of insurers and employers.
“Middlemen in the healthcare industry owe patients and taxpayers an explanation of their role. There’s far too much bureaucracy and too little transparency getting in the way of affordable, quality health care,” Mr. Grassley and Mr. Wyden told CNBC. “We’ve heard from pharmaceutical companies, and it’s only fair that the committee has the opportunity to ask questions of other players in the healthcare supply chain.”
The committee’s April hearing will be the third on drug pricing this year. Last month, seven pharmaceutical executives testified before Congress.
More articles on pharmacy:
Bristol-Myers urges shareholders to support Celgene takeover
Novartis to pay $23M to settle claims it used charity payments as kickbacks
Martin Shkreli reportedly running his pharma company from prison
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.